DFTX
Definium Therapeutics, Inc.
NASDAQ · USHealthcareMedical - Pharmaceuticals
$42.80-3.36%
Price as of Jul 20, 2026
DFTX growth
Definium Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- —
- EBIT
- -69.8%
- EPS
- —
- Free cash flow
- -56.3%
- Operating cash flow
- -56.3%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +17.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- -68.4%
- EBIT
- -60.0%
- Net income
- -69.1%
- EPS
- -33.8%
- Free cash flow
- -66.3%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.